Emergent BioSolutions has received a $44 million contract from the Centers for Disease Control and Prevention (CDC) to supply Vaccinia Immune Globulin Intravenous (VIGIV) therapeutic treatments, the company announced Thursday.
VIGIV is a compound that acts as a countermeasure to potential complications from a dose of the smallpox vaccine. This therapeutic would be housed in the Strategic National Stockpile (SNS) upon completion of the contract.
"Emergent is proud to support the U.S. government's implementation of its long-term stockpiling strategy. Thirteen years after VIGIV was first delivered to the SNS, VIGIV still remains a critical medical countermeasure in the government's preparedness efforts," Adam Havey, executive vice president and president of the biodefense division of Emergent BioSolutions, said. "We are pleased that CDC has exercised these contract options and look forward to successfully addressing their requirements."
Under this contract, the company is tasked with the securing of necessary plasma for manufacturing and partaking in additional activity to ensure the therapeutics' licensing from the Food and Drug Administration (FDA).
This is an addition to a contract between the CDC and Cangene Corp., which was acquired by Emergent in 2014. With this addition, the contract is valued at approximately $80 million. This countermeasure was originally delivered to the SNS in 2002, with FDA licensing being completed in 2005.